DenovAI Biotech

Company Overview

Snapshot

Founded in January 2023 by Kashif Sadiq, DenovAI Biotech operates with 11–50 employees. The company has secured funding across two rounds from six investors, with its most recent funding round occurring in February 2024.

Business overview

DenovAI Biotech is a Health Tech & Life Sciences company focused on developing foundational technology platforms for de novo protein design. The company's core technology leverages AI to design proteins completely from scratch, aiming to create next-generation therapeutics such as high-affinity antibodies, small protein and peptide biologics, and diagnostic reporters. DenovAI's platform is designed to accelerate the discovery process for high-affinity binders to specific epitopes, reducing development timelines from months to days and expanding therapeutic applications across various diseases. It serves the pharmaceuticals and biotechnology industries.

Strategic signal

In December 2023, DenovAI Biotech was highlighted for its use of artificial intelligence in discovering therapeutic antibodies and creating designer antibodies for various diseases. This signals the company's progress in leveraging AI for rapid and targeted drug discovery, indicating a strong potential for innovation in the biopharmaceutical sector and offering investors a view into its advanced R&D capabilities.

Company Intelligence Q&A

When was DenovAI Biotech founded?

DenovAI Biotech was founded in January 2023 by Kashif Sadiq.

What is DenovAI Biotech's primary focus?

DenovAI Biotech focuses on developing foundational technology platforms that use AI to design proteins de novo, aiming to create next-generation therapeutics like high-affinity antibodies, small protein and peptide biologics, and diagnostic reporters.

Which investors participated in DenovAI Biotech's February 2023 funding round?

In February 2023, DenovAI Biotech received funding from AION Labs and Pfizer Ventures.

What is the strategic impact of DenovAI Biotech's AI platform?

DenovAI Biotech's AI-based platform for rapid de novo antibody discovery aims to reduce the discovery process from months to days and broaden the scope of therapy to many more diseases by designing high-affinity binders to specific epitopes.

What was a key news highlight for DenovAI Biotech in December 2023?

In December 2023, news sources highlighted DenovAI Biotech's use of artificial intelligence to discover therapeutic antibodies and create designer antibodies for various diseases.